JP2012517478A5 - - Google Patents

Download PDF

Info

Publication number
JP2012517478A5
JP2012517478A5 JP2011550243A JP2011550243A JP2012517478A5 JP 2012517478 A5 JP2012517478 A5 JP 2012517478A5 JP 2011550243 A JP2011550243 A JP 2011550243A JP 2011550243 A JP2011550243 A JP 2011550243A JP 2012517478 A5 JP2012517478 A5 JP 2012517478A5
Authority
JP
Japan
Prior art keywords
use according
patients
hcv rna
weeks
rna levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011550243A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012517478A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/023978 external-priority patent/WO2010093843A2/en
Publication of JP2012517478A publication Critical patent/JP2012517478A/ja
Publication of JP2012517478A5 publication Critical patent/JP2012517478A5/ja
Pending legal-status Critical Current

Links

JP2011550243A 2009-02-12 2010-02-12 ペグ化インターフェロン、リバビリンおよびテラプレビルを含む、ｈｃｖ組合せ治療剤 Pending JP2012517478A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US15212009P 2009-02-12 2009-02-12
US61/152,120 2009-02-12
US17165409P 2009-04-22 2009-04-22
US61/171,654 2009-04-22
US25668609P 2009-10-30 2009-10-30
US61/256,686 2009-10-30
PCT/US2010/023978 WO2010093843A2 (en) 2009-02-12 2010-02-12 Hcv combination therapies

Publications (2)

Publication Number Publication Date
JP2012517478A JP2012517478A (ja) 2012-08-02
JP2012517478A5 true JP2012517478A5 (enExample) 2013-03-28

Family

ID=42315464

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011550243A Pending JP2012517478A (ja) 2009-02-12 2010-02-12 ペグ化インターフェロン、リバビリンおよびテラプレビルを含む、ｈｃｖ組合せ治療剤

Country Status (4)

Country Link
US (1) US20120039850A1 (enExample)
EP (1) EP2396028A2 (enExample)
JP (1) JP2012517478A (enExample)
WO (1) WO2010093843A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
NZ717373A (en) 2010-06-03 2017-11-24 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
WO2012109646A1 (en) 2011-02-11 2012-08-16 Vertex Pharmaceuticals Incorporated Treatment of hcv in hiv infection patients
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
DE202012012956U1 (de) 2011-10-21 2014-10-16 Abbvie Inc. Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen für die Verwendung zur Behandlung von HCV, umfassend Ribavirin aber nicht Interferon
SG2014011670A (en) 2011-10-21 2014-10-30 Abbvie Inc Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
WO2013116339A1 (en) * 2012-01-31 2013-08-08 Vertex Pharmaceuticals Incorporated High potency formulations of vx-950
WO2013168179A2 (en) * 2012-04-03 2013-11-14 Rubicon Research Private Limited Controlled release pharmaceutical formulations of antiviral agents
US10954567B2 (en) 2012-07-24 2021-03-23 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's Tyrosine Kinase (BTK)
JP2015536950A (ja) 2012-11-02 2015-12-24 ファーマサイクリックス，インク． Ｔｅｃファミリーキナーゼ阻害剤アジュバント療法
CA2942528A1 (en) 2014-03-20 2015-09-24 Pharmacyclics Inc. Phospholipase c gamma 2 and resistance associated mutations
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE674513T1 (de) 1992-12-29 1996-01-18 Abbott Lab Inhibitoren der retroviralen protease.
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
AU723730B2 (en) 1996-04-23 2000-09-07 Vertex Pharmaceuticals Incorporated Urea derivatives as inhibitors of IMPDH enzyme
DE69816280T2 (de) 1997-03-14 2004-05-27 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren des impdh-enzyms
US20040058982A1 (en) 1999-02-17 2004-03-25 Bioavailability System, Llc Pharmaceutical compositions
EE200100492A (et) 1999-03-19 2002-12-16 Vertex Pharmaceuticals Incorporated Ensüümi IMPDH inhibiitorid
EP1242058A1 (en) 1999-04-07 2002-09-25 Pfizer Products Inc. Use of cyp2d6 inhibitors in combination therapies
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
JP2004532184A (ja) 2001-01-22 2004-10-21 メルク　エンド　カムパニー　インコーポレーテッド Ｒｎａ依存性ｒｎａウィルスポリメラーゼ阻害薬としてのヌクレオシド誘導体
CA2369711A1 (en) 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
CA2369970A1 (en) 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
WO2004013300A2 (en) 2002-08-01 2004-02-12 Pharmasset Inc. Compounds with the bicyclo[4.2.1]nonane system for the treatment of flaviviridae infections
CA2413705A1 (en) 2002-12-06 2004-06-06 Raul Altman Use of meloxicam in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7098231B2 (en) 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
JP2006517960A (ja) 2003-02-18 2006-08-03 ファイザー インコーポレイテッド Ｃ型肝炎ウイルスの阻害剤、それを使用する組成物および治療法
CA2516018C (en) 2003-03-05 2011-08-23 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
WO2004101605A1 (en) 2003-03-05 2004-11-25 Boehringer Ingelheim International Gmbh Hepatitis c inhibiting compounds
AU2004240704B9 (en) 2003-05-21 2009-10-22 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor compounds
WO2005018330A1 (en) 2003-08-18 2005-03-03 Pharmasset, Inc. Dosing regimen for flaviviridae therapy
US6933760B2 (en) 2003-09-19 2005-08-23 Intel Corporation Reference voltage generator for hysteresis circuit
US7642235B2 (en) 2003-09-22 2010-01-05 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
AR045870A1 (es) * 2003-10-11 2005-11-16 Vertex Pharma Terapia de combinacion para la infeccion de virus de hepatitis c
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2549851C (en) 2004-01-21 2012-09-11 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis c virus
RS52931B (sr) 2004-02-20 2014-02-28 Boehringer Ingelheim International Gmbh Inhibitori virusne polimeraze
US20050187192A1 (en) 2004-02-20 2005-08-25 Kucera Pharmaceutical Company Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses
ZA200700030B (en) 2004-06-08 2009-06-24 Vertex Pharma Pharmaceutical compositions
MY141025A (en) * 2004-10-29 2010-02-25 Vertex Pharma Dose forms
EP2340836A1 (en) 2006-02-27 2011-07-06 Vertex Pharmceuticals Incorporated Co-crystals comprising VX-950 and their pharmaceutical compositions
BRPI0708957A2 (pt) 2006-03-20 2011-06-28 Vertex Pharma composições farmacêuticas
CN101494979A (zh) 2006-03-20 2009-07-29 沃泰克斯药物股份有限公司 药物组合物
EP2463284A1 (en) 2007-02-27 2012-06-13 Vertex Pharmceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
CN101854936A (zh) 2007-05-21 2010-10-06 弗特克斯药品有限公司 包含vx-950的剂型及其给药方案
WO2009061395A2 (en) * 2007-11-05 2009-05-14 Vertex Pharmaceuticals Incorporated Hcv combination therapies
MX2010011580A (es) * 2008-04-23 2010-11-09 Vertex Pharma Tratamiento de infecciones por virus de hepatitis c con telaprevir (vx-950) en pacientes que no responden al tratamiento con interferon-alfa-2a-2b pegilado y ribavirina.
US20110165119A1 (en) * 2008-06-10 2011-07-07 Maria Gloria Beumont Telaprevir dosing regimen
CA2738477A1 (en) * 2008-09-24 2010-04-01 Robert S. Kauffman Therapeutic regimen comprising peg-interferon, ribavirin and vx-950 for the treatment of hepatitis

Similar Documents

Publication Publication Date Title
JP2012517478A5 (enExample)
JP2014530874A5 (enExample)
JP2013518124A5 (enExample)
JP2013533858A5 (enExample)
JP2013155188A5 (enExample)
JP2018052983A5 (enExample)
MX2012008652A (es) Terapias para tratar infeccion por virus de hepatitis c.
HRP20170056T2 (hr) Terapija male učestalosti glatiramer acetatom
JP2012193216A5 (enExample)
SI2709613T1 (en) Procedures for the treatment of HCV
HRP20170358T1 (hr) Inhibitori histonskih demetilaza
MD4430B1 (ro) Compoziţii şi metode de tratament al hepatitei virale C
JP2010528013A5 (enExample)
HK1198869A1 (en) Combination treatments for hepatitis c
JP2013541583A5 (enExample)
JP2018513188A5 (enExample)
RU2013148779A (ru) Лечение инфекции вируса гепатита в по отдельности или в комбинации с вирусом гепатита дельта и родственных заболеваний печени
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
NZ625592A (en) Compositions and methods for the treatment of hepatic diseases and disorders
JP2015532293A5 (ja) 糖尿病患者における心不全の治療用組成物
JP2012503669A5 (enExample)
NZ598465A (en) Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
NZ588655A (en) Treatment of hepatitis c virus infections with telaprevir (vx-950) in patients non-responsive to treatment with pegylated interfer0n-alpha-2a/2b and ribavirin
JP2012508256A5 (enExample)
JP2011500650A5 (enExample)